{"preliminary_commentary":{"by_channel":{"x_thread":8},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03499808\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["isatuximab"]],"indication":"relapsed and/or refractory AL amyloidosis","name":"SWOG S1702","nct_id":"NCT03499808","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=swog-s1702-nct03499808. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive isatuximab IV on days 1, 8, 15, and 22 of course 1 and on days 1 and 15 of subsequent courses. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.","label":"Treatment (isatuximab)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2023-09-19","type":"ACTUAL"},"conditions":["Amorphous, Eosinophilic, and Acellular Deposit","Constipation","Diarrhea","Early Satiety","Gastrointestinal Hemorrhage","Hepatomegaly","Lymphadenopathy","Macroglossia","Nausea","Primary Systemic Amyloidosis","Purpura","Recurrent Primary Amyloidosis","Refractory Primary Amyloidosis"],"enrollment":{"count":43,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Isatuximab","otherNames":["Hu 38SB19","SAR 650984","SAR650984"],"type":"BIOLOGICAL"},{"name":"Laboratory Biomarker Analysis","otherNames":[],"type":"OTHER"}],"last_update":"2025-09-09","lead_sponsor":"SWOG Cancer Research Network","official_title":"A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-08-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Assess Efficacy by Confirmed Overall Hematologic Response","timeFrame":"From date of enrollment until progression or death due to any cause, whichever occurs first, assessed up to 4 years"}],"references":[{"citation":"Parker TL, Rosenthal A, Sanchorawala V, Landau HJ, Campagnaro EL, Kapoor P, Neparidze N, Girnius S, Hagen P, Scott EC, Hoering A, Durie BGM, Orlowski RZ. Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702). Blood. 2025 Nov 20;146(21):2507-2516. doi: 10.1182/blood.2024027962.","pmid":"40925099","type":"DERIVED"}],"start_date":{"date":"2018-06-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis","url":"https://clinicaltrials.gov/study/NCT03499808"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/swog-s1702-nct03499808"}